The objective of this case study was to elucidate the effect of photobiomodulation (PBM) on the microbiome.
Background:
The gut microbiome has been identified as a key component of health, with gut dysbiosis, characterized by decreased microbial diversity and an altered microbial composition, being recognized as instrumental in many diseases and disorders. Previous research has suggested that the gut microbiome can be favorably altered in animal models using PBM.
Materials and methods:
The participant had their microbiome tested on nine occasions, three times before any treatment, three times after radiotherapy and commencement of immunotherapy for breast cancer, and three times after PBM treatment. The PBM treatment consisted of infrared laser treatment (904 nm; 700 Hz pulse frequency, 861.3 total joules) to the abdomen three times per week for 11 weeks.
Results:
The microbiome of the participant showed significant changes in diversity after PBM treatment, but not after cancer therapy, with an increase in the number of known beneficial bacteria (Akkermansia, Faecalibacterium, and Roseburia) and decrease in the number of potentially pathogenic genera.
Conclusions:
The results suggested the possibility that PBM may alter the microbiome and thus it represents a therapeutic avenue for chronic diseases with otherwise limited treatment options.
Get full access to this article
View all access options for this article.
References
1.
MaruvadaP, LeoneV, KaplanLM, ChangEB. The human microbiome and obesity: moving beyond associations. Cell Host Microbe, 2017; 22:589–599.
2.
BurzSD, MonnoyeM, PhilippeC, et al.Fecal microbiota transplant from human to mice gives insights into the role of the gut microbiota in non-alcoholic fatty liver disease (NAFLD). Microorganisms, 2021; 9:199.
3.
SampsonTR, DebeliusJW, ThronT, et al.Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell, 2016; 167:1469–1480.e12.
4.
LiN, WangQ, WangY, et al.Fecal microbiota transplantation from chronic unpredictable mild stress mice donors affects anxiety-like and depression-like behavior in recipient mice via the gut microbiota-inflammation-brain axis. Stress, 2019; 22:592–602.
5.
SharonG, CruzNJ, KangD-W, et al.Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice. Cell, 2019; 177:1600–1618.e17.
6.
SettanniCR, IaniroG, Bibbò S, Cammarota G, Gasbarrini A. Gut microbiota alteration and modulation in psychiatric disorders: current evidence on fecal microbiota transplantation. Prog Neuropsychopharmacol Biol Psychiatry, 2021; 109:110258.
7.
GaoR, ZhuC, LiH, et al.Dysbiosis signatures of gut microbiota along the sequence from healthy, young patients to those with overweight and obesity. Obesity, 2018; 26:351–361.
8.
Singer-EnglarT, BarlowG, MathurR. Obesity, diabetes, and the gut microbiome: an updated review. Expert Rev Gastroenterol Hepatol, 2019; 13:3–15.
9.
RogersG, KeatingD, YoungR, WongM, LicinioJ, WesselinghS. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol Psychiatry, 2016; 21:738–748.
10.
CrovesyL, MastersonD, RosadoEL. Profile of the gut microbiota of adults with obesity: a systematic review. Eur J Clin Nutr, 2020; 74:1251–1262.
11.
ManorO, DaiCL, KornilovSA, et al.Health and disease markers correlate with gut microbiome composition across thousands of people. Nat Commun, 2020; 11:5206.
12.
VaisermanA, RomanenkoM, PivenL, et al.Differences in the gut Firmicutes to Bacteroidetes ratio across age groups in healthy Ukrainian population. BMC Microbiol, 2020; 20:221.
13.
ChelakkotC, ChoiY, KimD-K, et al.Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Exp Mol Med, 2018; 50:e450.
14.
de VosWM. Microbe profile: Akkermansia muciniphila: a conserved intestinal symbiont that acts as the gatekeeper of our mucosa. Microbiology, 2017; 163:646–648.
15.
EverardA, BelzerC, GeurtsL, et al.Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A, 2013; 110:9066–9071.
16.
LiJ, LinS, VanhouttePM, WooCW, XuA. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe−/− mice. Circulation, 2016; 133:2434–2446.
17.
OuZ, DengL, LuZ, et al.Protective effects of Akkermansia muciniphila on cognitive deficits and amyloid pathology in a mouse model of Alzheimer's disease. Nutr Diabetes, 2020; 10:12.
18.
DepommierC, EverardA, DruartC, et al.Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med, 2019; 25:1096–1103.
19.
ZhangT, LiQ, ChengL, BuchH, ZhangF. Akkermansia muciniphila is a promising probiotic. Microb Biotechnol, 2019; 12:1109–1125.
20.
WilkinsLJ, MongaM, MillerAW. Defining dysbiosis for a cluster of chronic diseases. Sci Rep, 2019; 9:12918.
21.
DerrienM, BelzerC, de VosWM. Akkermansia muciniphila and its role in regulating host functions. Microb Pathog, 2017; 106:171–181.
22.
BezawadaN, PhangTH, HoldGL, HansenR. Autism spectrum disorder and the gut microbiota in children: a systematic review. Ann Nutr Metab, 2020; 76:16–29.
23.
RadisavljevicN, CirsteaM, Brett FinlayB. Bottoms up: the role of gut microbiota in brain health. Environ Microbiol, 2019; 21:3197–3211.
24.
VogtNM, KerbyRL, Dill-McFarlandKA, et al.Gut microbiome alterations in Alzheimer's disease. Sci Rep, 2017; 7:13537.
25.
LingZ, ZhuM, YanX, et al.Structural and functional dysbiosis of fecal microbiota in Chinese patients with Alzheimer's disease. Front Cell Dev Biol, 2021; 8:634069.
26.
NishiwakiH, ItoM, IshidaT, et al.Meta-analysis of gut dysbiosis in Parkinson's disease. Mov Disord, 2020; 35:1626–1635.
27.
MachielsK, JoossensM, SabinoJ, et al.A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut, 2014; 63:1275–1283.
28.
BjörkqvistO, RepsilberD, SeifertM, et al.Alterations in the relative abundance of Faecalibacterium prausnitzii correlate with changes in fecal calprotectin in patients with ileal Crohn's disease: a longitudinal study. Scand J Gastroenterol, 2019; 54:577–585.
29.
GanesanK, ChungSK, VanamalaJ, XuB. Causal relationship between diet-induced gut microbiota changes and diabetes: a novel strategy to transplant Faecalibacterium prausnitzii in preventing diabetes. Int J Mol Sci, 2018; 19:3720.
30.
van den MunckhofIC, KurilshikovA, ter HorstR, et al.Role of gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies. Obes Rev, 2018; 19:1719–1734.
31.
SilvaCCD, MonteilMA, DavisEM. Overweight and obesity in children are associated with an abundance of firmicutes and reduction of Bifidobacterium in their gastrointestinal microbiota. Child Obes, 2020; 16:204–210.
32.
LiZ, ZhuH, ZhangL, QinC. The intestinal microbiome and Alzheimer's disease: a review. Animal Model Exp Med, 2018; 1:180–188.
33.
ZengMY, InoharaN, NuñezG. Mechanisms of inflammation-driven bacterial dysbiosis in the gut. Mucosal Immunol, 2017; 10:18–26.
34.
RizzattiG, LopetusoLR, GibiinoG, BindaC, GasbarriniA. Proteobacteria: a common factor in human diseases. Biomed Res Int, 2017; 2017:9351507.
JinM, QianZ, YinJ, XuW, ZhouX. The role of intestinal microbiota in cardiovascular disease. J Cell Mol Med, 2019; 23:2343–2350.
37.
KandeelW, MeguidN, BjorklundG, et al.Impact of clostridium bacteria in children with autism spectrum disorder and their anthropometric measurements. J Mol Neurosci, 2020; 70:897–907.
38.
SymondsR. Treatment-induced mucositis: an old problem with new remedies. Br J Cancer, 1998; 77:1689–1695.
39.
TouchefeuY, MontassierE, NiemanK, et al.Systematic review: the role of the gut microbiota in chemotherapy-or radiation-induced gastrointestinal mucositis–current evidence and potential clinical applications. Aliment Pharmacol Ther, 2014; 40:409–421.
40.
SougiannisAT, VanderVeenBN, DavisJM, FanD, MurphyEA. Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience. Am J Physiol Gastrointest Liver Physiol, 2021; 320:G712–G719.
41.
Gerassy-VainbergS, BlattA, Danin-PolegY, et al.Radiation induces proinflammatory dysbiosis: transmission of inflammatory susceptibility by host cytokine induction. Gut, 2018; 67:97–107.
42.
MaoA, SunC, KatsubeT, WangB. A minireview on gastrointestinal microbiota and radiosusceptibility. Dose Response, 2020; 18:1559325820963859.
43.
ShinJ-H, ParkY-H, SimM, KimS-A, JoungH, ShinD-M. Serum level of sex steroid hormone is associated with diversity and profiles of human gut microbiome. Res Microbiol, 2019; 170:192–201.
44.
KelleyST, SkarraDV, RiveraAJ, ThackrayVG. The gut microbiome is altered in a letrozole-induced mouse model of polycystic ovary syndrome. PLoS One, 2016; 11:e0146509.
45.
FragiadakisGK, WastykHC, RobinsonJL, SonnenburgED, SonnenburgJL, GardnerCD. Long-term dietary intervention reveals resilience of the gut microbiota despite changes in diet and weight. Am J Clin Nutr, 2020; 111:1127–1136.
46.
VagianosK, ShaferLA, WitgesK, et al.Association between change in inflammatory aspects of diet and change in IBD-related inflammation and symptoms over 1 year: the manitoba living with IBD study. Inflamm Bowel Dis, 2021; 27:190–202.
47.
Sotos-PrietoM, BhupathirajuSN, MatteiJ, et al.Changes in diet quality scores and risk of cardiovascular disease among US men and women. Circulation, 2015; 132:2212–2219.
48.
WestmanEC, YancyWS, MavropoulosJC, MarquartM, McDuffieJR. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. Nutr Metab (Lond), 2008; 5:36.
49.
Di DanieleN, NoceA, VidiriMF, et al.Impact of mediterranean diet on metabolic syndrome, cancer and longevity. Oncotarget, 2017; 8:8947–8979.
50.
WieërsG, BelkhirL, EnaudR, et al.How probiotics affect the microbiota. Front Cell Infect Microbiol, 2020; 9:454.
51.
ValchevaR, DielemanLA. Prebiotics: definition and protective mechanisms. Best Pract Res Clin Gastroenterol, 2016; 30:27–37.
BicknellB, LiebertA, JohnstoneD, KiatH. Photobiomodulation of the microbiome: implications for metabolic and inflammatory diseases. Lasers Med Sci, 2018; 34:317–327.
54.
WangM, CaoJ, AmakyeWK, GongC, LiQ, RenJ. Mid infrared light treatment attenuates cognitive decline and alters gut microbiota community in APS/PSI mouse model. Biochem Biophys Res Commun, 2020; 523:60–65.
55.
ChenQ, WuJ, DongX, et al.Gut flora-targeted photobiomodulation therapy improves senile dementia in an Aß-induced Alzheimer's disease animal model. J Photochem Photobiol B, 2021; 216:112152.
56.
LuY, YangJ, DongC, FuY, LiuH. Gut microbiome-mediated changes in bone metabolism upon infrared light exposure in rats. J Photochem Photobiol B, 2021:217:112156.
57.
LiebertA, BicknellB, JohnstoneD, GordonL, KiatH, HamblinM. “Photobiomics”: can photobiomodulation alter the microbiome?. Photobiomodul Photomed Laser Surg, 2019; 37:681–693.
58.
HamblinMR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys, 2017; 4:337–361.
59.
TchkoniaT, MorbeckDE, Von ZglinickiT, et al.Fat tissue, aging, and cellular senescence. Aging Cell, 2010; 9:667–684.
60.
da Silveira CamposRM, DâmasoAR, MasquioDCL, et al.Low-level laser therapy (LLLT) associated with aerobic plus resistance training to improve inflammatory biomarkers in obese adults. Lasers Med Sci, 2015; 30:1553–1563.
61.
SilvaG, FerraresiC, de AlmeidaRT, et al.Insulin resistance is improved in high-fat fed mice by photobiomodulation therapy at 630 nm. J Biophotonics, 2020; 13:e201960140.
62.
de Oliveira FranciscoC, BeltrameT, HughsonRL, et al.Effects of light-emitting diode therapy (LEDT) on cardiopulmonary and hemodynamic adjustments during aerobic exercise and glucose levels in patients with diabetes mellitus: a randomized, crossover, double-blind and placebo-controlled clinical trial. Complement Ther Med, 2019; 42:178–183.
63.
PaolilloFR, Borghi-SilvaA, ArenaR, ParizottoNA, KurachiC, BagnatoVS. Effects of phototherapy plus physical training on metabolic profile and quality of life in postmenopausal women. J Cosmet Laser Ther, 2017; 19:364–372.
64.
JankowskiM, GawrychM, AdamskaU, CiescinskiJ, SerafinZ, CzajkowskiR. Low-level laser therapy (LLLT) does not reduce subcutaneous adipose tissue by local adipocyte injury but rather by modulation of systemic lipid metabolism. Lasers Med Sci, 2017; 32:475–479.
65.
Sene-FioreseM, DuarteFO, de Aquino JuniorAE, et al.The potential of phototherapy to reduce body fat, insulin resistance and “metabolic inflexibility” related to obesity in women undergoing weight loss treatment. Lasers Surg Med, 2015; 47:634–642.
66.
ShinJ, NohJ-R, ChangD-H, et al.Elucidation of Akkermansia muciniphila probiotic traits driven by mucin depletion. Front Microbiol, 2019; 10:1137.
67.
Di GioiaD, AloisioI, MazzolaG, BiavatiB. Bifidobacteria: their impact on gut microbiota composition and their applications as probiotics in infants. Appl Microbiol Biotechnol, 2014; 98:563–577.
68.
HemalathaR, OuwehandA, SaarinenM, PrasadU, SwethaK, BhaskarV. Effect of probiotic supplementation on total lactobacilli, bifidobacteria and short chain fatty acids in 2–5-year-old children. Microb Ecol Health Dis, 2017; 28:1298340.
69.
PicardC, FioramontiJ, FrancoisA, RobinsonT, NeantF, MatuchanskyC. Bifidobacteria as probiotic agents–physiological effects and clinical benefits. Aliment Pharmacol Ther, 2005; 22:495–512.
70.
MiquelS, MartinR, RossiO, et al.Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol, 2013; 16:255–261.
71.
BenusRF, van der WerfTS, WellingGW, et al.Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects. Br J Nutr, 2010; 104:693–700.
72.
Tamanai-ShacooriZ, SmidaI, BousarghinL, et al.Roseburia spp.: a marker of health?. Future Microbiol, 2017; 12:157–170.
73.
DuncanSH, HoldGL, BarcenillaA, StewartCS, FlintHJ. Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. Int J Syst Evol Microbiol, 2002; 52:1615–1620.
74.
BraheLK, Le ChatelierE, PriftiE, et al.Specific gut microbiota features and metabolic markers in postmenopausal women with obesity. Nutr Diabetes, 2015; 5:e159.
75.
YamashitaT, EmotoT, SasakiN, HirataKI. Gut microbiota and coronary artery disease. Int Heart J, 2016; 57:663–671.
76.
LippertK, KedenkoL, AntonielliL, et al.Gut microbiota dysbiosis associated with glucose metabolism disorders and the metabolic syndrome in older adults. Benef Microbes, 2017; 8:545–556.
77.
ToprakN, ÖzcanE, PekinT, YumukP, SoyletirG. Bacteraemia caused by Clostridium symbiosum: case report and review of the literature. Indian J Med Microbiol, 2014; 32:92–94.
78.
MarvaudJ-C, LambertT. Arr-cb is a rifampin resistance determinant found active or cryptic in Clostridium bolteae strains. Antimicrob Agents Chemother, 2017; 61:e00301–e00317.
79.
XieY-H, GaoQ-Y, CaiG-X, et al.Fecal Clostridium symbiosum for noninvasive detection of early and advanced colorectal cancer: test and validation studies. EBioMedicine, 2017; 25:32–40.
80.
PequegnatB, MonteiroMA. Carbohydrate scaffolds for the study of the autism-associated bacterium, Clostridium bolteae. Curr Med Chem, 2019; 26:6341–6348.
81.
OhkusaT, YoshidaT, SatoN, WatanabeS, TajiriH, OkayasuI. Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis. J Med Microbiol, 2009; 58:535–545.
82.
DehouxP, MarvaudJC, AbouelleilA, EarlAM, LambertT, DaugaC. Comparative genomics of Clostridium bolteae and Clostridium clostridioforme reveals species-specific genomic properties and numerous putative antibiotic resistance determinants. BMC Genomics, 2016; 17:819.
83.
BoJ, WangS, BiY, MaS, WangM, DuZ. Eggerthella lenta bloodstream infections: two cases and review of the literature. Future Microbiol, 2020; 15:981–985.
84.
LauSK, WooPC, WooGK, et al.Eggerthella hongkongensis sp. nov. and Eggerthella sinensis sp. nov., two novel Eggerthella species, account for half of the cases of Eggerthella bacteremia. Diagn Microbiol Infect Dis, 2004; 49:255–263.
85.
LeeM-R, HuangY-T, LiaoC-H, et al.Clinical and microbiological characteristics of bacteremia caused by Eggerthella, Paraeggerthella, and Eubacterium species at a university hospital in Taiwan from 2001 to 2010. J Clin Microbiol, 2012; 50:2053–2055.
86.
ChiranjeeviT, PrasadOH, PrasadUV, et al.Identification of microbial pathogens in periodontal disease and diabetic patients of South Indian population. Bioinformation, 2014; 10:241–245.
87.
SakamotoM, SuzukiN, MatsunagaN, et al.Parabacteroides gordonii sp. nov., isolated from human blood cultures. Int J Syst Evol Microbiol, 2009; 59:2843–2847.
NatividadJM, LamasB, PhamHP, et al.Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice. Nat Commun, 2018; 9:2802.
90.
RaabeVN, ShaneAL. Group B Streptococcus (Streptococcus agalactiae). Microbiol Spectr, 2019; 7:1–21.
91.
GlaserP, RusniokC, BuchrieserC, et al.Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease. Mol Microbiol, 2002; 45:1499–1513.
92.
De AngelisM, PiccoloM, VanniniL, et al.Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS One, 2013; 8:e76993.
93.
DoumateyAP, AdeyemoA, ZhouJ, et al.Gut microbiome profiles are associated with type 2 diabetes in urban Africans. Front Cell Infect Microbiol, 2020; 10:63.
94.
MondotS, LepageP, SeksikP, et al.Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery. Gut, 2016; 65:954–962.
95.
SankarasubramanianJ, AhmadR, AvuthuN, SinghAB, GudaC. Gut microbiota and metabolic specificity in ulcerative colitis and Crohn's disease. Front Med, 2020; 7:606298.
96.
HynönenU, RasinkangasP, SatokariR, et al.Isolation and whole genome sequencing of a Ruminococcus-like bacterium, associated with irritable bowel syndrome. Anaerobe, 2016; 39:60–67.
97.
ZhangX, ZhangD, JiaH, et al.The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med, 2015; 21:895–905.
98.
AverinaOV, KovtunAS, PolyakovaSI, SavilovaAM, RebrikovDV, DanilenkoVN. The bacterial neurometabolic signature of the gut microbiota of young children with autism spectrum disorders. J Med Microbiol, 2020; 69:558–571.
99.
PetrovV, SaltykovaI, ZhukovaI, et al.Analysis of gut microbiota in patients with Parkinson's disease. Bull Exp Biol Med, 2017; 162:734–737.
100.
AbellGC, CookeCM, BennettCN, ConlonMA, McOristAL. Phylotypes related to Ruminococcus bromii are abundant in the large bowel of humans and increase in response to a diet high in resistant starch. FEMS Microbiol Ecol, 2008; 66:505–515.
101.
DeMartinoP, CockburnDW. Resistant starch: impact on the gut microbiome and health. Curr Opin Biotechnol, 2020; 61:66–71.
102.
Eslami-SZ, Majidzadeh-AK, HalvaeiS, BabapiraliF, EsmaeiliR. Microbiome and breast cancer: new role for an ancient population. Front Oncol, 2020; 10:120.
103.
FaithJJ, GurugeJL, CharbonneauM, et al.The long-term stability of the human gut microbiota. Science, 2013; 341:1237439.
104.
FuBC, RandolphTW, LimU, et al.Temporal variability and stability of the fecal microbiome: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev, 2019; 28:154–162.
105.
Krasny-PaciniA, EvansJ. Single-case experimental designs to assess intervention effectiveness in rehabilitation: a practical guide. Ann Phys Rehabil Med, 2018; 61:164–179.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
